.Attributes Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires addition of patients with MASLD as well as dimension of liver results in cardio-- kidney-- metabolic trials, when records propose mechanistically probable benefits and medical safety-- and summarizes factors to consider for trial design and regulatory commendation.